Prognosis
Kenya Approves J&J, Pfizer Covid-19 Vaccines as Cases Surge
Photographer: Kiyoshi Ota/Bloomberg
This article is for subscribers only.
Kenya approved the emergency use of Johnson & Johnson and Pfizer Inc. Covid-19 vaccines, said Fred Siyoi, chief executive officer of the Pharmacy and Poisons Board.
The East African nation expects to receive 13 million J&J doses starting this month. Kenya’s plan to inoculate its entire adult population of 26 million people by end of 2022 is reliant on J&J vaccines. About 10 million people will be vaccinated by the end of December, President Uhuru Kenyatta said last month.